Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the Int

Logo BenzingaBenzinga
2023-06-09 13:15:00  • 9 mins

-- Data from the RLYB212 Phase 1b Proof-of-Concept Study to be Featured as an Oral Presentation at ISTH --

-- Company to Host Webcast Following ISTH Oral Presentation of RLYB212 --

Rallybio Corporation RLYB, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that results from the RLYB212 Phase 1b proof-of-concept study will be presented at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Data from the Phase 1b RLYB212 proof-of-concept study will be presented by Christof Geisen, M.D., as an oral presentation.

Details of the abstract presentation are as follows:

  • Title: Dose-Dependent Elimination of HPA-1a Platelets by Subcutaneous RLYB212, a Monoclonal Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
  • Presenting Author: Christof Geisen, M.D., Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Transfusion Service Baden-Wrttemberg-Hessen gGmbH, Frankfurt am Main, Germany.
  • Abstract Presentation Number: OC 02.1
  • Session Title: Bleeding and Neonatal Alloimmune Thrombocytopenia in Pregnancy
  • Session Date and Time: Saturday, June 24, 2023, from 13:00 - 14:15 (1:00 p.m. - 2:15 p.m. ET)
  • Presentation Time: 13:00 - 13:15 (1:00 p.m. - 1:15 p.m. ET), 12-minute presentation and 3-minute Q&A

The abstract can be accessed via the official ISTH 2023 Congress website at: https://www.isth2023.org/

Continue read on benzinga.com

Candel Therapeutics Inc CADLannounced updated activity data from its ongoing, open-label, phase 2 trial of CAN-2409 plus valacyclovir in combination with...
Logo BenzingaBenzinga
2023-09-26 16:46:11  • 1 min
(RTTNews) - IDEAYA Biosciences, Inc. (IDYA) said the FDA has granted Fast Track designation to development program investigating IDE161 for the treatment of...
Logo NasdaqNasdaq
2023-09-27 10:29:47  • 1 min
(RTTNews) - Evotec SE (EVO, EVOTF.PK) and Novo Nordisk A/S (NVO) announced Tuesday a translational drug discovery accelerator called LAB eN, which aims to...
Logo NasdaqNasdaq
2023-09-26 12:08:17  • 1 min
(RTTNews) - Biogen Inc. (BIIB) has completed the acquisition of Reata Pharmaceuticals, Inc. (RETA). As a result, Biogen has now acquired SKYCLARYS, and other...
Logo NasdaqNasdaq
2023-09-26 14:03:36  • 1 min
(RTTNews) - Pliant Therapeutics, Inc. (PLRX) reported positive data from INTEGRIS-PSC, a Phase 2a clinical trial of bexotegrast in patients with primary...
Logo NasdaqNasdaq
2023-09-26 12:35:24  • 1 min
Health care stocks were lower Tuesday afternoon with the NYSE Health Care Index falling 0.6% and the Health Care Select Sector SPDR Fund (XLV) down 0.8%. The...
Logo NasdaqNasdaq
2023-09-26 17:51:06  • 1 min
The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's CHRS on-body...
Logo BenzingaBenzinga
2023-09-25 19:35:07  • 1 min
Immunovant Inc IMVT, a unit of Roivant Sciences Ltd ROIV, announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in...
Logo BenzingaBenzinga
2023-09-26 13:33:10  • 1 min
(RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced Monday that the European Commission has granted conditional marketing authorization for TEPKINLY...
Logo NasdaqNasdaq
2023-09-25 12:50:51  • 1 min
Health care stocks were leaning lower premarket Tuesday, with the iShares Biotechnology ETF ( IBB ) was marginally declining and the Health Care Select...
Logo NasdaqNasdaq
2023-09-26 13:18:01  • 1 min
What happened Shares of Soleno Therapeutics (NASDAQ: SLNO) were up more than 372% as of 12:30 p.m. on Tuesday. The clinical stage biotech said its lead...
Logo NasdaqNasdaq
2023-09-26 16:51:44  • 1 min
(RTTNews) - Ionis Pharmaceuticals Inc. (IONS) announced positive results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia...
Logo NasdaqNasdaq
2023-09-26 11:54:17  • 1 min
Omega Therapeutics Inc OMGA announced preliminary data from the initial two dose level cohorts (n=8) from Part 1 of its Phase 1/2 MYCHELANGELO I study of...
Logo BenzingaBenzinga
2023-09-26 16:41:33  • 1 min
(RTTNews) - ZimVie Inc. (ZIMV) announced that on September 7, 2023, the FDA approved its Mobi-C Cervical Disc Hybrid Investigational Device Exemption...
Logo NasdaqNasdaq
2023-09-26 12:45:38  • 1 min
(RTTNews) - Biotechnology companies Dyadic International, Inc. (DYAI) and France's bYoRNA SAS announced Tuesday that they entered into a development and...
Logo NasdaqNasdaq
2023-09-26 14:06:30  • 1 min
In trading on Tuesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 2.9% on the day. Components of that ETF showing particular strength...
Logo NasdaqNasdaq
2023-09-26 16:52:28  • 1 min
(RTTNews) - Immunovant, Inc. (IMVT), a subsidiary of Roivant (ROIV), Tuesday reported positive initial data from the Phase 1 study of its drug candidate...
Logo NasdaqNasdaq
2023-09-26 11:05:05  • 1 min
(RTTNews) - Phathom Pharmaceuticals, Inc. (PHAT), a biopharmaceutical company focused on gastrointestinal or GI diseases, announced Tuesday the submission of...
Logo NasdaqNasdaq
2023-09-26 13:05:01  • 1 min
A study published this week linked the COVID-19 antiviral molnupiravir to new coronavirus mutations, raising questions about whether the drug could lead to...
Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to...
Logo BenzingaBenzinga
2023-09-26 14:52:49  • 1 min